Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, Key Genomics Teaming on Ovarian Cancer Treatment Test

NEW YORK (GenomeWeb News) – Transgenomic said today that it will work with Key Genomics to develop a molecular test to help physicians find out which ovarian cancer patients will respond to a certain drug treatment.
 
The test will couple Key Genomics’ coexpression extrapolation, or COXEN, predictive algorithm with Transgenomic’s DNA mutation detection analysis technology to predict epithelial carcinoma of the ovary.
 
Transgenomic said that its mutation and analysis technologies will “complement and enhance” the COXEN algorithm, which uses genomic and pharmacological response data about cancer lines to generate molecular response signatures to specific anti-cancer agents. The companies aim for the test to provide optimal therapy recommendations based on the specific characteristics of a patient’s tumor.
 
Because ovarian cancers are often diagnosed only after the tumor has spread beyond the ovary, getting “the best therapeutics option as quickly as possible is a key factor in survival,” Transgenomic CEO Craig Tuttle said in a statement. Using the COXEN-derived test that distinguishes which patients will benefit from a certain therapy, Tuttle said, “we believe physicians will be able to quickly direct ovarian cancer patients towards appropriate lines of therapy.”

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.